M&A Deal Summary

Polyventive Acquires Tri-Tex

On December 13, 2021, Polyventive acquired chemicals company Tri-Tex from SK Capital Partners

Acquisition Highlights
  • This is Polyventive’s 1st transaction in the Chemicals sector.
  • This is Polyventive’s 1st transaction in Canada.
  • This is Polyventive’s 1st transaction in Quebec.

M&A Deal Summary
Date 2021-12-13
Target Tri-Tex
Sector Chemicals
Buyer(s) Polyventive
Sellers(s) SK Capital Partners
Deal Type Add-on Acquisition

Target

Tri-Tex

St-Eustache, Quebec, Canada
Tri-Tex is a producer of high-performance specialty chemicals focused on the adhesive, sealants, surfactants, and textile & paper chemical markets. Tri-Tex was founded in 1882 and is headquartered in St-Eustache, Quebec.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Polyventive

Calhoun, Georgia, United States
Category Company
Sector Chemicals
DESCRIPTION

Polyventive is a manufacturer of specialty chemical solutions for the HI&I, Water Treatment, Personal Care, Construction, Soft Floor Covering, and Textile industries. Polyventive’s manufacturing, technical capabilities, applications expertise, and focus on solving customer problems has made it the first choice for industry leading solutions. Polyventive is based in Calhoun, Georgia.

DEAL STATS #
Overall 1 of 1
Sector (Chemicals) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2021) 1 of 1

Seller(S) 1

SELLER

SK Capital Partners

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2007
PE ASSETS 4.9B USD
Size Large
Type Sector Agnostic
DESCRIPTION

SK Capital Partners is a private investor in mature and middle-market companies located throughout North America. SK Capital focuses on companies with opportunities for substantial business improvement and strong growth prospects. The Firm looks to invest $100 to $200 million of equity in transactions valued up to $500 million. Prospective businesses typically generate $50 to $500 million in revenues and at least $100 million in EBITDA. Areas of interest include specialty materials, chemicals and healthcare. The Firm will consider a variety of transaction situations, including buyouts, recapitalizations, growth equity financings, and corporate carve-outs. SK Capital Partners was spun out of Arsenal Capital Partners and became independent in 2007. SK Capital Partners is based in New York City.

DEAL STATS #
Overall 9 of 14
Sector (Chemicals) 5 of 9
Type (Add-on Acquisition) 5 of 7
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2021) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-26 Wavelength Pharmaceuticals

Petah Tikva, Israel

Wavelength Pharmaceuticals is a developer and manufacturer of generic APIs and finished dose forms (“FDF”) with operations primarily located in Israel and supporting functions in the U.S. and India. The Business has a global customer base and a broad array of products that leverage its specialized manufacturing capabilities and core competency in complex chemistries. Wavelength Pharmaceuticals is based in Petah Tikva, Israel.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-02 Florachem

Jacksonville, Florida, United States

Florachem is a distributor of specialty aroma chemicals and essential oils to the fragrance, flavor, consumer, and industrial products industries. Florachem was founded in 1988 and is based in Jacksonville, Florida.

Buy -
Mergr

Product

Company

Legal